Adeno-associated virus-mediated brain delivery of 5-lipoxygenase modulates the AD-like phenotype of APP mice

Molecular Neurodegeneration

Volumn 7, Issue 1, 2012, Pages

  Chu, Jin ^a   Giannopoulos, Phillip F ^a   Ceballos Diaz, Carolina ^b   Golde, Todd E ^b   Pratico, Domenico ^a  

^a TEMPLE UNIVERSITY   (United States)

^b UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

5 Lipoxygenase; Alzheimer's disease; amyloid beta; animal model

Indexed keywords

ADAM10 ENDOPEPTIDASE; AMYLOID PRECURSOR PROTEIN; ARACHIDONATE 5 LIPOXYGENASE; BETA SECRETASE 1; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; GAMMA SECRETASE; NICASTRIN; PARVOVIRUS VECTOR; PEN 2 PROTEIN; PROTEIN; PS1 PROTEIN; UNCLASSIFIED DRUG; SECRETASE;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN; BRAIN TISSUE; COGNITIVE DEFECT; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; GENE OVEREXPRESSION; MEMORY DISORDER; MOUSE; NONHUMAN; PATHOGENESIS; PHENOTYPE; ADENO ASSOCIATED VIRUS; ANIMAL; DISEASE MODEL; FEMALE; GENE VECTOR; GENETICS; HUMAN; MEMORY; METABOLISM; NERVE CELL; PATHOLOGY; PHYSIOLOGY; TRANSGENIC MOUSE;

ADENO-ASSOCIATED VIRUS; ANIMALIA; MUS;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN PRECURSOR; AMYLOID PRECURSOR PROTEIN SECRETASES; ANIMALS; ARACHIDONATE 5-LIPOXYGENASE; BRAIN; DEPENDOVIRUS; DISEASE MODELS, ANIMAL; FEMALE; GENETIC VECTORS; HUMANS; MEMORY; MICE; MICE, TRANSGENIC; NEURONS; PHENOTYPE;

EID: 84855414647     PISSN: None     EISSN: 17501326     Source Type: Journal    
DOI: 10.1186/1750-1326-7-1     Document Type: Article

References (25)

1. 5-Lipoxygenase: regulation of expression and enzyme activity. Radmark O, Werz O, Steinhilber D, Samuelsson B, Trends Biochem Sci 2007 32 332 341 10.1016/j.tibs.2007.06.002 17576065 (Pubitemid 47021417)
2. Arachidonate 5-lipoxyygenase and its activating protein: prominent hippocampal expression and role in somatostatin signaling. Lammers CH, Schweitzer P, Facchinetti P, Arrang JM, Madamba SG, Siggins GR, Piomelli D, J Neurochem 1996 66 147 152 8522947 (Pubitemid 26010775)
3. Age-associated up-regulation of neuronal 5-lipoxygenase expression: putative role in neuronal vulnerability. Uz T, Pesold C, Longone P, Manev H, FABEB J 1998 123 439 449 (Pubitemid 28146523)
4. The 5-lipoxygenase enzymatic pathway in the mouse brain: young versus old. Chinnici CM, Yao Y, Pratic D, Neurobiol Aging 2007 28 1457 1462 10.1016/j.neurobiolaging.2006.06.007 16930777 (Pubitemid 47081230)
5. Increased 5-Lipooxygenase imunoreactivity in hippocampus of patients with Alzheimer' diseases. Ikonomovic MD, Abrahamson EE, Uz T, Manev H, Dekosky ST, J Histochem Cytochem 2008 56 1065 1073 10.1369/jhc.2008.951855 18678882
6. 5-Lipoxygenase gene disruption reduces amyloid- pathology in a mouse model of Alzheimer's disease. Firuzi O, Zhuo J, Chinnici CM, Wisniewski T, Pratic D, FASEB J 2008 22 1169 1178 17998412 (Pubitemid 351519971)
7. 5-Lipoxygenase as an endogenous modulator of amyloid beta formation in vivo. Chu J, Pratic D, Ann Neurol 2011 69 34 46 10.1002/ana.22234 21280074
8. 5-Lipoxygenase (5-LOX) promoter polymorphism in patients with early-onset and late-onset Alzheimer's disease. Qu T, Manev R, Manev H, J Neuropsychiatry Clin Neurosci 2001 13 304 305 10.1176/appi.neuropsych.13.2.304 11449041 (Pubitemid 32499684)
9. Pharmacological blockade of 5-Lipoxygenase improves the amyloidotic phenotype of an Alzheimer's disease transgenic mouse model. Chu J, Pratic D, Am J Pathol 2011 178 4 1762 1769 10.1016/j.ajpath.2010.12.032 21435457
10. Behavioral characterization of the Tg2576 transgenic model of Alzheimer's disease through 19 months. King DL, Arendash GW, Physiology & Behavior 2002 75 5 627 642 10.1016/S0031-9384(02)00639-X 22224113 (Pubitemid 34521825)
11. Behavioral changes in transgenic mice expressing both amyloid precursor protein and presenilin-1 mutations: lack of association with amyloid deposits. Holcomb LA, Gordon MN, Jantzen P, Hsiao K, Duff K, Morgan D, Behav Genet 1999 29 3 177 85 10.1023/A:1021691918517 10547924 (Pubitemid 29500635)
12. Luteinizing hormone modulates cognition and amyloid-beta deposition in Alzheimer APP transgenic mice. Casadesus G, Webber KM, Atwood CS, Pappolla MA, Perry G, Bowen RL, Smith MA, Biochim Biophys Acta 2006 1762 4 447 52 16503402 (Pubitemid 43344306)
13. PEN-2 and APH-1 coordinately regulate proteolytic processing of presenilin 1. Luo WJ, Wang H, Li H, Kim BS, Shah S, Lee HJ, Thinakaran G, Kim TW, Yu G, Xu H, J Biol Chem 2003 278 7850 7854 10.1074/jbc.C200648200 12522139 (Pubitemid 36800519)
14. Transcriptional regulation of Pen-2, a key component of the -secretase complex, by CREB. Wang R, Zhang YW, Sun P, Liu R, Zhang X, Zhang X, Xia K, Xia J, Xu H, Zhang Z, Mol Cell Biol 2006 26 1347 1354 10.1128/MCB.26.4.1347-1354. 2006 16449647 (Pubitemid 43202561)
15. Novel rat Alzheimer's disease models based on AAV-mediated gene transfer to selectively increase hippocampal A levels. Lawlor PA, Bland RJ, Das P, Price RW, Holloway V, Smithson L, Dicker BL, During MJ, Young D, Golde TE, Mol Neurodeg 2007 2 11 10.1186/1750-1326-2-11 (Pubitemid 47145662)
16. Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. Hsiao K, Chapman P, Nilsen S, Eckman C, Harigaya Y, Younkin S, Yang F, Cole G, Science 1996 274 99 102 10.1126/science.274.5284.99 8810256 (Pubitemid 26332733)
17. Adeno-associated virus vectors serotyped with AAV8 capsid are more efficient than AAV-1 or -2 serotypes for widespread gene delivery to the neonatal mouse brain. Broekman ML, Comer LA, Hyman BT, Sena-Esteves M, Neuroscience 2006 138 501 510 10.1016/j.neuroscience.2005.11.057 16414198 (Pubitemid 43255560)
18. Intracranial adeno-associated virus mediated delivery of antipan amylodi A, amyloid 40, and amyloid 42 single-chain variable fragments attenuates plaque pathology in amyloid precursor protein mice. Levites Y, Jansen K, Smithson LA, Dakin R, Holloway VM, Das P, Golde TE, J Neurosci 2006 26 11923 11928 10.1523/JNEUROSCI.2795-06.2006 17108166 (Pubitemid 44772103)
19. BRI2(ITM2b) inhibits Abeta deposition in vivo. Kim J, Miller VM, Levites Y, Jansen West K, Zwiziski GW, Moore BD, Troendle FJ, Bann M, Verbeeck C, Price RW, Smithson L, Sonoda L, Wagg K, Rangachari V, Zou F, Younkin SG, Graff-Radford N, Dickson D, Rosenberry T, Golde TE, J Neurosci 2008 28 6030 6036 10.1523/JNEUROSCI.0891-08.2008 18524908
20. Amelioration of the Alzheimer's disease phenotype by absence of 12/15-lipoxygenase. Yang H, Zhuo J, Chu J, Chinnici C, Pratic D, Biol Psych 2010 68 10 922 929 10.1016/j.biopsych.2010.04.010
21. Acceleration of brain amyloidosis in an Alzheimer's disease mouse model by a folate, vitamin B6 and B12-deficient diet. Zhuo J, Pratic D, Exp Gerontol 2010 45 3 195 201 10.1016/j.exger.2009.12.005 20005283
22. Diet-induced hyperhomocysteinemia increases Amyloid- formation and deposition in a mouse model of Alzheimer's disease. Zhuo J, Portugal G, Kruger W, Wang H, Gould T, Pratic D, Current Alz Res 2010 7 2 140 149 10.2174/156720510790691326
23. Normalization of hyperhomocysteinemia improves cognitive deficits and ameliorates brain amyloidosis of a transgenic mouse model of Alzheimer's disease. Zhuo J, Pratic D, FASEB J 2010 24 10 3895 3902 10.1096/fj.10-161828 20519634
24. A role for 12/15Lipoxygenase in the Amyloid Precursor Protein metabolism. Succol F, Pratic D, J Neurochem 2007 103 380 387 17877641 (Pubitemid 47404209)
25. -Ct method. Kenneth JL, Thomas DS, Method 2002 25 402 408